KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Net Income (2017 - 2025)

Historic Net Income for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $1.1 billion.

  • Takeda Pharmaceutical's Net Income fell 1937.44% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $14.0 billion, marking a year-over-year increase of 3346.36%. This contributed to the annual value of $709.9 million for FY2025, which is 2899.72% down from last year.
  • Takeda Pharmaceutical's Net Income amounted to $1.1 billion in Q4 2025, which was down 1937.44% from $7.5 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Net Income high stood at $7.5 billion for Q3 2025, and its period low was $487.8 million during Q3 2022.
  • For the 5-year period, Takeda Pharmaceutical's Net Income averaged around $2.1 billion, with its median value being $1.4 billion (2024).
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 64822.38% in 2021, then tumbled by 7115.93% in 2022.
  • Over the past 5 years, Takeda Pharmaceutical's Net Income (Quarter) stood at $761.5 million in 2021, then fell by 11.55% to $673.6 million in 2022, then surged by 161.65% to $1.8 billion in 2023, then dropped by 25.02% to $1.3 billion in 2024, then dropped by 19.37% to $1.1 billion in 2025.
  • Its Net Income stands at $1.1 billion for Q4 2025, versus $7.5 billion for Q3 2025 and $2.6 billion for Q2 2025.